Clinical Trial Update: Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating bumetanide oral liquid in children and adolescents with autism spectrum disorder has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• BUMETANIDE (bumetanide)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Autism Spectrum Disorder (ASD) | Phase 3 | Status: TERMINATED